Mayne Pharma Files Legal Complaint Against TherapeuticsMD

Mayne Pharma Group ( (AU:MYX) ) has shared an update.

Mayne Pharma Group Limited has filed a complaint against TherapeuticsMD, Inc. in the United States District Court for the District of Delaware, alleging breach of contract and fraud. The complaint seeks over US$11.5 million in damages due to alleged misrepresentations by TherapeuticsMD about commercialisation assets sold to Mayne Pharma. Additionally, Mayne Pharma has filed a motion to dismiss TherapeuticsMD’s legal proceeding, which it believes to be without merit.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to provide better, safer, and more accessible medicines. The company is a leader in dermatology and women’s health and offers contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has developed new oral drug delivery systems that have been commercialized in various products worldwide.

YTD Price Performance: -0.40%

Average Trading Volume: 915,341

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$402.2M

See more data about MYX stock on TipRanks’ Stock Analysis page.